NIH launches clinical trials of COVID-19 blood-clotting treatments

The National Institutes of Health yesterday announced the launch of two of three planned, worldwide phase 3 clinical trials of varying types of blood thinners to treat adults with COVID-19.

Trials will include hospitalized and non-hospitalized patients; the expected third trial will later focus on those discharged after hospitalization for moderate-to-severe disease.

NIH said research shows many COVID-19 patients who died suffered from blood clots throughout their bodies; these blood thinners, known as ACTIV-4 antithrombotics, could provide insights for care.